Better access to patient information would enable researchers to answer new questions with existing data, validate findings, and combine the power from individual studies.
Difficulties in obtaining patient data on the effects of heart failure drugs from previously published clinical trials are making it impossible to assess the outcomes of these drugs on patients, according to an article published yesterday in the BMJ.
These problems accessing data from clinical trials means that only part of the evidence base is available, and this may lead to erroneous clinical decisions, writes lead author Robert Fleetcroft, MD, clinical lecturer in general practice at the Norwich Medical School at the University of East Anglia, UK.
The research team carried out a systematic review of the effectiveness of heart failure drugs for patients with minor symptoms. They found 30 studies that looked at the effect of these drugs -- beta blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers -- on heart failure. However, none of the studies included enough data to assess outcomes for patients with the varying degrees of minor symptoms required.
Fleetcroft and collegues said they were surprised at the difficulties they faced, even though most studies were published between the 1990s and 2010. Four had been published since 2010.
"We need central national repositories for trial data based in the country of the trial sponsor," they noted, adding that mechanisms of data sharing must be developed and coordinated actions from funders, journals, ethics, committees, and national guideline developing bodies are vital.
Better access to patient information would enable researchers to answer new questions with existing data, validate findings, and combine the power from individual studies, and it may also prevent selective reporting and research fraud, according to Fleetcroft et al.
Furthermore, bodies involved in national guidelines have a role to play, and it is unacceptable for these groups to make decisions about new drugs based on clinical effectiveness data that are not in the public domain, they stated. Such transparency is essential to bolster trust in the process of evaluation of new treatments.
Finally, they recommend that research ethics and funding committees should make future access to data a mandatory requirement, and funders should cover the costs of archiving data and journals should require evidence of archived data.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.